Ajanta Pharma Ltd (AJPH.NS)

AJPH.NS on National Stock Exchange of India

9:35am IST
Change (% chg)

Rs-29.50 (-2.44%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Ajanta Pharma Limited is a holding company. The Company is a specialty pharmaceutical company engaged in developing, producing and marketing a range of branded and generic formulations. Its business includes branded generics in emerging markets of Asia and Africa, generics in the developed markets of the United States and... (more)


Beta: 1.44
Market Cap(Mil.): Rs106,365.50
Shares Outstanding(Mil.): 88.01
Dividend: 7.00
Yield (%): 1.08


  Industry Sector
P/E (TTM): -- 30.87 15.95
EPS (TTM): -- -- --
ROI: -- 14.31 15.19
ROE: -- 15.61 13.87

BRIEF-India's Ajanta Pharma gets final approval for Entacapone tablets from U.S. FDA

* Says received the final approval for Entacapone tablets from US FDA

04 Sep 2017

BRIEF-Ajanta Pharma says U.S. unit launches eletriptan hydrobromide tablets

* Says launched eletriptan hydrobromide tablets in US market through our wholly owned subsidiary, Ajanta Pharma USA Inc. Source text for Eikon: Further company coverage:

31 Aug 2017

BRIEF-India's Ajanta Pharma June-qtr profit falls

* June quarter profit 947.9 million rupees versus 1.20 billion rupees year ago

09 Aug 2017

BRIEF-Ajanta Pharma says Ganga Exports sold 2.7 mln shares of co

* Says Ganga Exports has sold 2.7 million equity shares of company representing 3.07 pct of paid up capital Source text for Eikon: Further company coverage:

11 Jul 2017

BRIEF-Ajanta Pharma March-qtr consol profit rises

* March quarter consol net profit 1.14 billion rupees versus profit 1.09 billion rupees year ago

03 May 2017

BRIEF-Ajanta Pharma's Dahej facility does not get form 483 after FDA inspection

* Ajanta Pharma Ltd says co's Dahej facility was inspected by FDA from April 3-7, 2017; no form 483 was issued Source text: [This is to inform you that Company's formulation facility at Dahej was inspected by US FDA from 3rd to 7th April, 2017. At the end of the inspection, no Form 483 was issued to the Company] Further company coverage:

10 Apr 2017

Earnings vs. Estimates